On September 14, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium. The virtual event will take place on September 23, 2022 (Press release, Kineta, SEP 14, 2022, View Source;utm_medium=rss&utm_campaign=kineta-cso-thierry-guillaudeux-invited-to-participate-at-the-2nd-annual-vista-virtual-symposium [SID1234619549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to join leading immuno-oncology experts in discussing the latest advances in anti-VISTA immunotherapies," said Dr. Guillaudeux. "VISTA is an important myeloid checkpoint with a unique mechanism of action bridging innate and adaptive immunity. Anti-VISTA therapies have great potential to improve cancer treatment outcomes in a variety of solid tumors, especially for patients resistant to standard of care therapies including first generation immune checkpoint inhibitors."

Dr. Guillaudeux will join leading researchers and clinicians in immunology to discuss new insights into VISTA, a promising therapeutic target for cancer. The symposium will focus on VISTA’s function and applicability in cancer immunology, as well as the latest research and development in programs targeting VISTA.